BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/26/2025 10:16:43 AM | Browse: 105 | Download: 681
 |
Received |
|
2024-12-20 03:25 |
|
Peer-Review Started |
|
2024-12-20 03:26 |
|
First Decision by Editorial Office Director |
|
2025-01-10 09:46 |
|
Return for Revision |
|
2025-01-10 09:46 |
|
Revised |
|
2025-01-15 10:03 |
|
Publication Fee Transferred |
|
2025-01-17 14:37 |
|
Second Decision by Editor |
|
2025-02-25 02:50 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-02-25 10:32 |
|
Articles in Press |
|
2025-02-25 10:32 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-03-14 01:44 |
|
Publish the Manuscript Online |
|
2025-03-26 10:16 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Diagnosis and treatment of pulmonary lymphoepithelioma-like carcinoma: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Feng-Ling Huang, Min Luo, Zhen-Mei He, Yong-Qi Shen and Guan-Da Liu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Chinese Medicine Administration Bureau of Guangxi Zhuang Autonomous Region |
GXZYB20220472 |
|
| Corresponding Author |
Guan-Da Liu, MD, Department of Pharmacology and Clinical Pharmacy, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, No. 10 Huadong Road, Nanning 530000, Guangxi Zhuang Autonomous Region, China. rkjp2024@163.com |
| Key Words |
Pulmonary lymphoepithelioma-like carcinoma; Epstein-Barr virus; Anlotinib; Toripalimab; Case report |
| Core Tip |
We report a case of a 38-year-old man who was diagnosed with right pulmonary lymphoepithelioma-like carcinoma (PLELC). Chest computed tomography (CT) revealed a mass in the medial segment of the middle lobe of the right lung, with lymph node metastasis in the mediastinum and right hilum of the lung. CT-guided lung tumor biopsy was performed and the postoperative pathological examination combined with immune phenotype analysis and in situ hybridization confirmed PLELC. Standard molecular testing for patients with non-small cell lung cancer was negative and programmed cell death ligand-1 expression was about 2%. However, the patient declined radiotherapy and chemotherapy treatment. Consequently, immunotherapy was administered, which included toripalimab 240 mg on day 1 and anlotinib 10 mg on days 1-14 for 10 cycles, followed by a maintenance dose of anlotinib 10 mg daily every 3 weeks. As a result, his progression-free survival reached 48 months. PLELC is a rare primary epithelial lung cancer. Currently, there is no standard treatment for PLELC. A combination of toripalimab and anlotinib may benefit patients with advanced diseases who have not received systematic anti-tumor therapy. However, its long-term efficacy requires further comprehensive research and validation. |
| Publish Date |
2025-03-26 10:16 |
| Citation |
Huang FL, Luo M, He ZM, Shen YQ, Liu GD. Diagnosis and treatment of pulmonary lymphoepithelioma-like carcinoma: A case report. World J Clin Oncol 2025; 16(4): 104413 |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i4/104413.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i4.104413 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
